Company News and Media Releases

View All News Voir toutes les nouvelles

Jamieson Wellness Inc. Reports First Quarter 2023 Results, Maintains Full Year Outlook and Declares First Quarter Dividend

May 04, 2023

Consolidated revenue increased 31.9% to $136.7 million; Jamieson Brands revenue increased 30.0%; Adjusted EBITDA1 increased $3.6 million to $24.5 million; Adjusted diluted earnings per share2 was $0.21

Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) today reported its first quarter results for the period ended March 31, 2023. All amounts are expressed in Canadian dollars.

“Jamieson Wellness entered 2023 in a position of strength, having laid a solid foundation for continued growth across our business in 2022,” said Mike Pilato, President and CEO of Jamieson Wellness. “Our Jamieson Brands segment delivered another exceptional quarter with a 30% revenue increase, reflecting organic growth, the impact of our U.S. acquisition, and the continued demand for our brands, globally.

“As expected, revenue grew at a faster rate than Adjusted EBITDA in the quarter, which posted a 17% increase. This reflects strategic investments in brand building activities and expanding our team and operations in the U.S. and China, while ensuring our Canadian business remains healthy and grows its leadership position. We are confident in our outlook for the year and look forward to continuing to support our consumers’ health and wellness journeys while driving value for all our stakeholders.”

First Quarter Highlights

  • Maintained strong momentum in Canada as consumer consumption outpaced shipments
  • Over-delivered revenue expectations in the U.S. led by stronger than expected consumer consumption
  • Began production of key new and improved youtheory product in anticipation of shipping in Q2
  • Met continued strong demand for the Jamieson brand in China as COVID-19 restrictions lifted
  • Grew team in China in anticipation of transition to an owned distribution and operations model in Q2
  • Launched a sustainable partner program in support of ESG commitments to help identify, measure and monitor sustainability progress and risk within the Company’s supply chain

First Quarter Financial Results Consolidated Summary

All comparisons are with the first quarter of 2022

  • Consolidated revenue increased 31.9% to $136.7 million with both Jamieson Brands and Strategic Partners segments contributing to growth
  • Gross profit margin3 decreased by 110 basis points to 35.5%, driven by segment mix led by the over delivery of expectations in youtheory and Strategic Partners, both of which have inherently lower profit margins
  • EBITDA1 increased $0.9 million to $19.3 million; Adjusted EBITDA1 increased by $3.6 million to $24.5 million, due to higher volumes and gross profit, offset by increased SG&A expenses including investments to support growth in the U.S. and China
  • Net earnings decreased 27.5% to $7.1 million; Adjusted net earnings1 decreased 18.0% to $8.8 million, driven by the reasons noted above and offset by borrowing costs related to the U.S. acquisition and associated higher prevailing interest rates, the impact of which appears higher in the first quarter due to its seasonally lower volumes
  • Diluted earnings per share was $0.17; Adjusted diluted earnings per share2 was $0.21 and includes dilution as a result of the shares issued in the youtheory transaction

Summary of Segment Results

All comparisons are with the first quarter of 2022

Jamieson Brands

  • Revenue was $108.1 million, an increase of 30.0% or $24.9 million
  • Canada revenue increased 2.4% as consumer consumption paced ahead of shipments in the quarter, due to the typical seasonal influx of shipments in Q4 2022 to support cold and flu season
  • U.S. (youtheory) contributed $22.2 million in revenue driven by stronger than expected consumer consumption and e-commerce growth of over 33.0%
  • China revenue increased 36.6% due to continued category growth led by higher consumer sell-through in the cross-border e-commerce channel and the removal of COVID-19 restrictions
  • International revenue declined an expected 15.5%, reflecting slowing declines in Eastern Europe and the timing of promotional replenishments in the Caribbean and South East Asia regions in the prior year
  • Gross profit increased $8.2 million to $43.8 million; gross profit margin3 decreased by 230 basis points as expected, due to the inherently lower youtheory gross margin profile and product mix
  • Adjusted EBITDA1 increased $1.1 million to $20.7 million driven by higher volumes and associated gross profit, offset by investments in SG&A to support growth in the U.S. and China; Adjusted EBITDA margin2 decreased by 440 basis points to 19.1% due to the factors noted above

Strategic Partners

  • Revenue was $28.6 million, an increase of 39.7% or $8.1 million, due to timing of customer orders and lapping of a softer Q1 2022
  • Gross profit increased $2.4 million to $4.7 million
  • Gross profit margin3 increased by 510 basis points to 16.5%
  • Adjusted EBITDA1 increased by $2.5 million to $3.9 million; Adjusted EBITDA margin2 increased by 660 basis points to 13.5%

Balance Sheet and Cash Flow

  • The Company generated $7.9 million in cash from operations compared to $17.1 million in Q1 2022
  • Cash from operating activities before working capital considerations of $13.1 million decreased by $2.2 million compared to Q1 2022 due to decreased earnings including realized acquisition costs
  • Cash from working capital decreased by $6.9 million driven by timing of collections and inventory payments
  • As at March 31, 2023, the Company had $124.8 million in cash and available revolving and swingline facilities and net debt1 of $375.2 million

1 This is a non-IFRS financial measure. See the “Non-IFRS and Other Financial Measures” section of this press release for more information on each non-IFRS financial measure.
2 This is a non-IFRS ratio. See the “Non-IFRS and Other Financial Measures” section of this press release for more information on each non-IFRS ratio.
3 This is a supplementary financial measure. See the “Non-IFRS and Other Financial Measures” section of this press release for more information on each supplementary financial measure.

Maintaining Fiscal 2023 Outlook

The Company is maintaining its outlook for the 2023 fiscal year and continues to anticipate the following:

  • Revenue in a range of $670.0 to $700.0 million, which represents annual growth of 22.0% to 28.0%
  • Adjusted EBITDA in a range of $140.0 to $146.0 million
  • Adjusted diluted earnings per share in a range of $1.62 to $1.72
  • For additional details on the Company’s fiscal 2023 outlook, including guidance for the second quarter of 2023, refer to the “Outlook” section in the management’s discussion and analysis of financial condition and results of operations (“MD&A”) for the three months ended March 31, 2023

Declaration of First Quarter Dividend

The board of directors of the Company authorized and declared a cash dividend for the first quarter of 2023:

  • $0.17 per common share, or approximately $7.1 million in the aggregate
  • Paid on June 15, 2023 to all common shareholders of record at the close of business on June 1, 2023
  • The Company has designated this dividend as an “eligible dividend” for the purposes of the Income Tax Act (Canada)

Closing of Previously Announced Distributor Transaction in China

Also announced today, the Company has completed the previously announced purchase of the operating assets of its distributor partner in China. The purchase allows the Company to directly operate its sales, marketing and distribution activities in the world’s second largest VMS market. With full control of its brand and value chain in China, the Company expects to accelerate its ability to bring more world-class, high-quality vitamins, minerals, and supplements to a broader base of Chinese consumers. Details on the completed transaction can be found in a separate media release issued this afternoon.

Consolidated Financial Statements and Management’s Discussion and Analysis

The Company’s unaudited condensed consolidated interim financial statements and accompanying notes as at and for the three months ended March 31, 2023 and related MD&A are available under the Company’s profile on SEDAR at www.sedar.com and on the Investor Relations section of the Company’s website at https://investors.jamiesonwellness.com.

Conference Call

Management will host a conference call to discuss the Company’s first quarter 2023 results at 5:00 p.m. ET today, May 4, 2023. To access:

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness also offers a variety of VMS products under its youtheory, Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com.

Jamieson Wellness’ head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company’s anticipated results and its outlook for its 2023 revenue, Adjusted EBITDA and Adjusted diluted earnings per share. Words such as “expect”, “anticipate”, “intend”, “may”, “will”, “estimate” and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under “Risk Factors” in the Company’s Annual Information Form dated March 30, 2023 and under the “Risk Factors” section in the MD&A filed today, May 4, 2023. This information is based on the Company’s reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company’s results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See “Forward-looking Information” and “Risk Factors” within the MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

 

Jamieson Wellness Inc.

Selected Consolidated Financial Information

In thousands of Canadian dollars, except share and per share amounts

 
Three months ended
March 31

2023

2022

 
Revenue

136,725

103,675

Cost of sales

88,209

65,728

Gross profit

48,516

37,947

 
Gross profit margin

35.5%

36.6%

 
Selling, general and administrative expenses

32,392

21,620

Share-based compensation

1,496

1,142

Earnings from operations

14,628

15,185

 
Operating margin

10.7%

14.6%

 
Foreign exchange loss

163

463

Interest expense and other financing costs

6,302

1,278

Earnings before income taxes

8,163

13,444

Provision for income taxes

1,098

3,703

Net earnings

7,065

9,741

Adjusted net earnings

8,808

10,744

 
EBITDA

19,306

18,438

Adjusted EBITDA

24,508

20,945

 
Adjusted EBITDA margin

17.9%

20.2%

 
Weighted average number of shares
Basic

41,775,989

40,442,265

Diluted

42,791,481

41,731,184

 
Earnings per share attributable to common shareholders:
Basic, earnings per share

0.17

0.24

Diluted, earnings per share

0.17

0.23

Adjusted diluted, earnings per share

0.21

0.26

 

Jamieson Wellness Inc.

Consolidated Statements of Financial Position

In thousands of Canadian dollars

 

March 31,
2023

December 31,
2022

Assets
Current assets
Cash

16,293

26,240

Accounts receivable

110,671

160,798

Inventories

186,810

154,488

Derivatives

5,540

6,580

Prepaid expenses and other current assets

6,735

4,298

326,049

352,404

Non-current assets
Property, plant and equipment

110,431

111,709

Goodwill

272,841

272,916

Intangible assets

365,801

367,205

Deferred income tax

3,411

3,029

Total assets

1,078,533

1,107,263

 
Liabilities
Current liabilities
Accounts payable and accrued liabilities

128,456

142,566

Income taxes payable

995

7,387

Derivatives

33

-

Current portion of other long-term liabilities

4,346

4,852

133,830

154,805

Long-term liabilities
Long-term debt

391,470

400,000

Post-retirement benefits

956

929

Deferred income tax

57,903

58,007

Other long-term liabilities

61,341

61,931

Total liabilities

645,500

675,672

 
Shareholders' equity
Share capital

309,974

307,200

Contributed surplus

16,872

17,115

Retained earnings

85,441

85,483

Accumulated other comprehensive income

20,746

21,793

Total shareholders' equity

433,033

431,591

Total liabilities and shareholders' equity

1,078,533

1,107,263

 

Jamieson Wellness Inc.

Segment Information

In thousands of Canadian dollars, except as otherwise noted

 
Jamieson Brands
 
Three months ended
March 31

2023

2022

$ Change % Change
 
Revenue

108,110

 

83,188

 

24,922

 

30.0

%

 
Gross profit

43,801

 

35,617

 

8,184

 

23.0

%

Gross profit margin

40.5

%

42.8

%

-

 

(2.3

%)

 
Selling, general and administrative expenses

30,663

 

20,051

 

10,612

 

52.9

%

Normalized selling, general and administrative expenses

27,120

 

19,197

 

7,923

 

41.3

%

 
Share-based compensation

1,496

 

1,142

 

354

 

31.0

%

 
Earnings from operations

11,642

 

14,424

 

(2,782

)

(19.3

%)

Operating margin

10.8

%

17.3

%

-

 

(6.5

%)

 
Normalized earnings from operations

15,185

 

15,278

 

(93

)

(0.6

%)

Normalized operating margin

14.0

%

18.4

%

-

 

(4.4

%)

 
Adjusted EBITDA

20,651

 

19,540

 

1,111

 

5.7

%

Adjusted EBITDA margin

19.1

%

23.5

%

-

 

(4.4

%)

 
 
Strategic Partners
 
Three months ended
March 31

2023

2022

$ Change % Change
 
Revenue

28,615

 

20,487

 

8,128

 

39.7

%

 
Gross profit

4,715

 

2,330

 

2,385

 

102.4

%

Gross profit margin

16.5

%

11.4

%

-

 

5.1

%

 
Selling, general and administrative expenses

1,729

 

1,569

 

160

 

10.2

%

Normalized selling, general and administrative expenses

1,729

 

1,521

 

208

 

13.7

%

 
Earnings from operations

2,986

 

761

 

2,225

 

292.4

%

Operating margin

10.4

%

3.7

%

-

 

6.7

%

 
Normalized earnings from operations

2,986

 

809

 

2,177

 

269.1

%

Normalized operating margin

10.4

%

3.9

%

-

 

6.5

%

 
Adjusted EBITDA

3,857

 

1,405

 

2,452

 

174.5

%

Adjusted EBITDA margin

13.5

%

6.9

%

-

 

6.6

%

Non-IFRS and Other Financial Measures

This press release makes reference to certain financial measures, including non-IFRS financial measures that are historical, non-IFRS measures that are forward-looking, non-GAAP ratios and supplementary financial measures. Management uses these financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company’s business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS. The Company uses the following non‑IFRS financial measures: “EBITDA”, “Adjusted EBITDA” and “Adjusted net earnings”, the most directly comparable financial measure for each that is disclosed in its financial statements being net earnings, “normalized SG&A”, “normalized earnings from operations”, “cash from operating activities before working capital considerations” and “net debt”, the most directly comparable financial measures for each that is disclosed in its financial statements being gross profit, SG&A, earnings from operations, cash flows from operating activities, and long-term debt, respectively, the following non-IFRS ratios: “Adjusted EBITDA margin”, “Adjusted diluted earnings per share”, “normalized operating margin”, and the following supplementary financial measures: “gross profit margin” and “operating margin” to provide supplemental measures of the Company’s operating performance and thus highlight trends in the Company’s core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non‑IFRS and supplementary financial measures in order to prepare annual operating budgets and to determine components of management compensation. For an explanation of the composition of each such measure and the usefulness and additional uses of each by management, see the “How we Assess the Performance of our Business” section of the MD&A, which is incorporated by reference. See below for a quantitative reconciliation of each non-IFRS financial measure to its most directly comparable financial measure disclosed in the Company’s financial statements to which the measure relates.

The following tables provide a quantitative reconciliation of net earnings to EBITDA, Adjusted EBITDA, and Adjusted net earnings, as well as SG&A to normalized SG&A, earnings from operations to normalized earnings from operations, each of which are non-IFRS financial measures (see the “Non-IFRS and Other Financial Measures” of this press release for further information on each non-IFRS financial measure) for the three months ended March 31, 2023 and March 31, 2022.

 

Reconciliation of Non-IFRS Financial Measures

In thousands of Canadian dollars

 
Three months ended
March 31

2023

2022

 
Net earnings

7,065

 

9,741

 

Add:
Provision for income taxes

1,098

 

3,703

 

Interest expense and other financing costs

6,302

 

1,278

 

Depreciation of property, plant, and equipment

3,467

 

2,658

 

Amortization of intangible assets

1,374

 

1,058

 

 
Earnings before interest, taxes, depreciation, and amortization (EBITDA)

19,306

 

18,438

 

Add EBITDA adjustments:
Share-based compensation(1)

1,496

 

1,142

 

Foreign exchange loss

163

 

463

 

Acquisition related costs (2)

2,801

 

-

 

IT system implementation (3)

670

 

739

 

Other

72

 

163

 

Adjusted EBITDA

24,508

 

20,945

 

Provision for income taxes

(1,098

)

(3,703

)

Interest expense and other financing costs

(6,302

)

(1,278

)

Depreciation of property, plant, and equipment

(3,467

)

(2,658

)

Amortization of intangible assets

(1,374

)

(1,058

)

Share-based compensation(4)

(1,454

)

(1,142

)

Tax deduction from vesting of certain share-based awards (5)

(1,022

)

-

 

Tax effect of normalization adjustments

(983

)

(362

)

Adjusted net earnings

8,808

 

10,744

 

 
 
Three months ended
March 31

2023

2022

 
Selling, general and administrative expenses

32,392

 

21,620

 

Acquisition related cost(2)

(2,801

)

-

 

IT system implementation(3)

(670

)

(739

)

Other

(72

)

(163

)

Normalized selling, general and administrative expenses

28,849

 

20,718

 

 
Earnings from operations

14,628

 

15,185

 

Acquisition related cost(2)

2,801

 

-

 

IT system implementation(3)

670

 

739

 

Other

72

 

163

 

Normalized earnings from operations

18,171

 

16,087

 

Normalized operating margin

13.3

%

15.5

%

(1)

 

The Company’s share-based compensation expense pertains to our long-term incentive plan (the “LTIP”) (refer to “Share-based compensation”), with performance-based share units (“PSUs”), time-based restricted share units (“RSUs”), and deferred share units (“DSUs”) expenses, along with associated payroll taxes.

(2)

 

Current quarter expense mainly pertains to legal and consulting costs associated with the acquisition of our distributor in China, as well as integration costs relating to our acquisition of youtheory which closed on July 19, 2022.

(3)

 

Current quarter expense mainly pertains to development costs for our Enterprise Resource Planning (“ERP”) system implementation. Unlike other system improvement projects with costs capitalized, due to its cloud-based nature, these system implementation costs are expensed accordingly.

(4)

 

Costs pertaining to our LTIP, excluding PSUs granted to certain employees relating to business combinations.

(5)

 

The vesting of share-based compensation provides a tax benefit during the period in which the awards are settled.

 

Investor and Media Contact Information:
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com

Source: Jamieson Wellness Inc.
Categories: Press Releases
View All News Voir toutes les nouvelles